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Streptococcal prosthetic joint infections (PJIs) treated with de-
bridement, exchange of removable parts, antibiotics, and im-
plant retention within 3 weeks from symptom onset had an 
implant survival rate of 97.9% and an implant survival rate 
without suppressive antimicrobials of 80.9%. Treatment cen-
tralization for acute streptococcal PJIs to specialized centers 
makes excellent cure rates possible.
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A not-so-good prognosis for streptococcal prosthetic join infec-
tions (PJIs) treated with debridement, antibiotics, and implant 
retention (DAIR) has been reported by a large international 
multicenter study, with a failure rate of 42% [1]. This high failure 
rate might be because the removable parts were only exchanged 
in 53% of the cases, and the DAIR was not limited to acute cases 
(ie, ≤3 weeks from symptom onset). The treatment practices 
also varied greatly between the 52 participating hospitals, with 
a mean of 9 PJIs treated per hospital. However, better outcomes 
for streptococcal PJIs treated with DAIR have also been reported 
[2, 3].
Finding high failure rates following DAIRs in streptococcal 
PJIs is alarming, especially when an unsuccessful DAIR might 
be a risk factor for failure following 2-stage exchange [4–6]. 
However, DAIR is a very attractive treatment option because, 
when successful, it is tolerated even by elderly and morbid 
patients, requires a shorter hospital stay, allows faster recovery, 
and has a lower treatment cost [7].
Our aim in this study was to examine the success rate for 
DAIR-treated streptococcal PJIs in a specialized tertiary care 
center when the patient selection, surgical technique, and 
antimicrobials used were appropriate. This was used to verify 
whether a recommendation for centralizing acute PJI treatment 
to specialized centers was justifiable.
METHODS
A retrospective analysis of consecutive DAIR-treated strepto-
coccal PJIs in a single specialized tertiary care center (Helsinki 
University Hospital, Peijas Hospital) between 1 January 2008 
and 15 April 2017 was performed for 54 cases. In this joint re-
placement unit, nearly 3000 hip or knee arthroplasties are per-
formed annually, with demanding PJI treatment centralized 
from the district. The strictly obeyed inclusion criteria were 
removable parts were exchanged, DAIR was performed within 
3 weeks of symptom onset, and DAIR was the first surgical pro-
cedure for PJI treatment.
Seven patients were excluded: 4 because the removable parts 
were not exchanged (eg, monoblock tibial component), 2 for 
a DAIR delay >3 weeks, and 1 because the DAIR was not the 
first operation. The outcomes of these excluded patients were 
3 patients were with long-term suppressive antimicrobial, 1 pa-
tient died because of heart insufficiency 1 month after DAIR, the 
hip prosthesis was removed from 1 patient because of repeated 
hip dislocations, and 2 patients were cured and no suppressive 
antimicrobials were used.
There were 13 patients in this study who were earlier included 
in the multicenter study of Lora-Tamayo et al [1]. According to 
the Infectious Diseases Society of America, a PJI was defined as 
the presence of a sinus tract communicating with the prosthesis, 
acute inflammation upon histological examination, purulence 
surrounding the prosthesis, and/or ≥2 evaluable samples yield-
ing the same organism [8]. Enterococci or obligate anaerobes 
such as peptostreptococci were not included.
The following data were retrieved from the medical records: 
age at DAIR, sex, infected joint, comorbidities, immunosup-
pressive agent use, penicillin allergy, infection type (post-
operative or hematogenous, defined as an acute PJI after 
an uneventful postoperative course and after confirmed or 
suspected bacteremia), microbiological findings, C-reactive 
protein (CRP) value, surgical procedures performed, and anti-
microbial agents used. The patients were followed from DAIR 
until prosthetic joint removal, death, or the chart review. At 
the time of discharge, each patient was reminded to contact 
the operating hospital if they had any infection relapse symp-
toms. With very uniform healthcare in the area, the general 
practitioners and paramedics know to refer a patient with a 
painful or infected prosthetic joint to the correct center. The 
follow-up of 1 monomicrobial streptococcal PJI ended with a 
new hematogenous infection caused by a different bacterium, 
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Staphylococcus lugdunensis, later in the follow-up after an un-
eventful antimicrobial-free period.
Mean values and standard deviations (SDs) were calculated 
for the normally distributed continuous variables, whereas me-
dian values and interquartile ranges (IQRs) were calculated 
to portray the nonnormally distributed data. Pearson χ2 and 
Fisher exact tests were used as univariate analyses for the cat-
egorical variables, and the Mann-Whitney U test was used for 
the continuous variables. Multivariate tests were performed, but 
they were underpowered (data not shown).
RESULTS
In our center, 47 acute streptococcal PJIs were treated with DAIRs, 
including removable part exchanges, between 1 January 2008 and 
15 April 2017. Of the infected joints, 26 (55.3%) were hips and 21 
(44.7%) were knees. There were more hematogenous origin PJIs 
[29/47 (61.7%)] than postoperative [18/47 (38.3%)]. The blood 
cultures were positive in 19.1% of the cases. The mean age of the 
patients was 66.4 years (SD, 12.3; range, 21–92), 40.4% were males, 
10.6% had rheumatoid arthritis, and 8.5% were taking immuno-
suppressive medications. One patient (2.1%) had chronic renal 
failure (baseline creatinine >150 mg/L). The CRP mean (highest 
value before DAIR) was 272 mg/L (SD, 121.7; range, 8–521).
DAIR was performed a median of 5 days after symptom onset 
(IQR, 3–8) and a median of 3 days (IQR, 2–5) after admission. 
Orthopedic surgeons specialized in arthroplasty performed 
all DAIRs.
In 91.5% of the cases, a streptococcus was the only pathogen 
(8.5% were polymicrobial infections). The causative strepto-
cocci were group A streptococci (n = 2), Streptococcus agalac-
tiae (n = 11), group G streptococci (16), Streptococcus anginosus 
group (n = 5), Streptococcus salivarius (n = 1), other viridans 
streptococci (n  =  10), and Streptococcus pneumoniae (n  =  2). 
All the streptococci were sensitive to penicillin, except the 2 
S.  pneumoniae. The minimal inhibitory concentration (MIC) 
for penicillin was 1 mg/L. In the polymicrobial infections, the 
other microorganisms included 3 Staphylococcus epidermidis, 
2 Staphylococcus hemolyticus, and 1 other coagulase-negative 
staphylococcus. All the polymicrobial PJIs were postoperative 
infections with discharging wounds. Among the postoperative 
PJIs, the median time interval from symptom onset to DAIR 
was significantly longer among polymicrobial PJIs compared to 
monomicrobial (10.5 vs 3.5 days; P = .005).
All the antimicrobial treatments were planned and followed 
up by an infectious disease specialist, and all the patients 
received intravenous β-lactams for a median of 28 days (range, 
14–38). The total antimicrobial treatment median time was 
90  days. The most common oral antimicrobials used were 
amoxicillin, clindamycin, and cephalexin. Rifampin was used 
for more than 21 days in 5 cases (10.6%), either for a polymi-
crobial infection that included staphylococcus (4 cases) or for 
S. pneumoniae with a penicillin MIC of 1 mg/L.
After the median follow-up time of 2.9 years (IQR, 1.5–4.9), 
97.9% of the original prostheses were retained (95% confidence 
interval [CI], 88.9%–99.6%], and 80.9% of the patients had the 
original prosthetic joint without antimicrobial treatment (95% 
CI, 67.5%–89.6%). None of the patients died because of the infec-
tion. One (2.1%) prosthesis was removed because of a persistent 
infection, and a 2-stage exchange was performed. No relapses 
emerged after discontinuing the antimicrobial treatment.
At the chart review, a long-term suppressive antimicrobial 
was in use in 8 (17.0%) patients. Suppressive antimicrobial use 
was reduced during the study period, with 28.6% and 7.7% of 
the patients treated between 2008 and 2013 and between 2014 
and 2017, respectively (P = .115). No suppressive antimicrobials 
were indicated by clinical signs of an active infection. The sup-
pressive antimicrobial indications were an unwillingness to risk 
relapse due to several comorbidities or a tumor megaprosthesis.
In the univariate analyses, the statistically significant risk 
factors for either implant removal or long-term suppressive 
antimicrobial treatment were a hematogenous origin (P = .009; 
odds ratio, 1.45; 95% CI, 1.14%–1.85%), higher American 
Society of Anesthesiologists class (P = .023), and age (P = .047).
DISCUSSION
The implant survival rate in DAIR-treated acute streptococcal 
PJIs was high when they were performed in a specialized center 
within 3 weeks from symptom onset, the removable parts were 
exchanged, and optimal antimicrobials were used under the 
guidance of an infectious disease specialist. In the monomicro-
bial infections, rifampin was not needed.
When compared to a large international multicenter study of 
DAIR-treated streptococcal PJIs [1], the current study achieved 
clearly higher implant and antimicrobial-free implant survival 
rates. The exchange of removable parts has been shown to im-
prove survival [1, 9]. In our specialized center, a wide variety 
of removable parts are available. All the patients are operated 
by orthopedic surgeons specialized in arthroplasty, and the sur-
geons always perform a meticulous open debridement of the 
infected joint. The patients who did not meet the strict inclusion 
criteria had clearly poorer outcomes. When performed accord-
ing to a strict protocol, DAIR has exhibited better outcomes in 
previous studies [2, 10]. In our study, median time from onset of 
symptoms to DAIR was short at 5 days, and from admission to 
DAIR it was 3 days. This rapid access to treatment may explain 
in part the successive outcomes [10].
In the professional treatment of PJIs, the multidisciplinary 
team includes an infectious disease specialist, microbiology la-
boratory, and orthopedic surgeons. In our cases, all antimicrobial 
treatments were planned by infectious disease specialist, and the 
majority of the PJIs were treated with β-lactams. Rifampin was 
not needed to cure the monomicrobial streptococcal PJIs. This is 
in line with most previous publications [11, 12], except the mul-
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In that study, the rifampin usage varied widely between the 
centers, and it could be associated with some other differences 
in the surgical or medical treatment protocols, for example, a 
higher biofilm burden because the removable parts were not 
exchanged.
Especially in the early years of DAIR use in our center, long-
term suppressive antimicrobials were used occasionally with 
vulnerable patients. After the first DAIR results were evaluated 
in our unit, the proportion of long-term suppressive antimi-
crobials was reduced in 2013, and no infection relapses have 
emerged to date. However, the 17% proportion of patients on 
suppressive antimicrobials was a limitation of our study.
International multicenter studies are excellent for collecting a 
large number of rare disease cases and performing very valuable 
risk factor analyses. However, according to our study, centraliz-
ing the DAIR gives excellent results. Thus, we recommend that 
acute PJI treatment only be performed in high-volume centers 
with specialized orthopedic surgeons, and infectious disease 
specialists who have an interest in PJI treatment, and with a 
wide variety of prosthesis components available.
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